

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Advancing strategies to increase adherence to oral therapies in onco-hematology: protocol for a randomized controlled study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055814
Article Type:	Protocol
Date Submitted by the Author:	02-Aug-2021
Complete List of Authors:	<p>Passardi, Alessandro; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Department of Medical Oncology Serra, Patrizia; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Unit of Biostatistic and Clinical Trials Caffo, Orazio; Provincia autonoma di Trento Azienda Provinciale per i Servizi Sanitari, Department of Medical Oncology Masini, Carla; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Oncology Pharmacy Unit Brugugnoli, Erika; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Oncology Pharmacy Unit Vespignani, Roberto; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, IT Service Giardino, Valeria; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Unit of Biostatistics and Clinical Trials Petracci, Elisabetta ; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Unit of Biostatistics and Clinical Trials Bartolini, Giulia; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Department of Medical Oncology Sullo, Francesco; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Department of Medical Oncology Anesi, Cecilia; Provincia autonoma di Trento Azienda Provinciale per i Servizi Sanitari, Department of Medical Oncology Dianti, Marco; Bruno Kessler Foundation, eHealth Unit Eccher, Claudio; Bruno Kessler Foundation, eHealth Unit Piras, Enrico; Bruno Kessler Foundation, eHealth Unit Gios, Lorenzo; TrentinoSalute 4.0, Competence Center for Digital Health Campomori, Annalisa; Presidio Ospedaliero Santa Chiara, Hospital Pharmacy Unit Oberosler, Valentina; Presidio Ospedaliero Santa Chiara, Hospital Pharmacy Unit Forti, Stefano; Bruno Kessler Foundation, eHealth Unit</p>
Keywords:	Information management < BIOTECHNOLOGY & BIOINFORMATICS, ONCOLOGY, ORAL MEDICINE



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Original research

Advancing strategies to increase adherence to oral therapies in onco-hematology: protocol for a randomized controlled study

Alessandro Passardi,¹ Patrizia Serra,² Orazio Caffo,³ Carla Masini,⁴ Erika Brugugnoli,⁴ Roberto Vespignani,⁵ Valeria Giardino,² Elisabetta Petracci,² Giulia Bartolini,¹ Francesco Sullo,¹ Cecilia Anesi,³ Marco Dianti,⁶ Claudio Eccher,⁶ Enrico Maria Piras,⁶ Lorenzo Gios,⁷ Annalisa Campomori,⁸ Valentina Oberosler,⁸ Stefano Forti⁶

¹ Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

² Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

³ Department of Medical Oncology, Azienda Provinciale per i Servizi Sanitari, Trento, Italy

⁴ Oncology Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

⁵ IT Service, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

⁶ Center for Information and Communication Technology, eHealth Unit, Fondazione “Bruno Kessler”, Trento, Italy

⁷ TrentinoSalute 4.0, Competence Center for Digital Health, Trento, Italy

1
2
3
4 ⁸ Hospital Pharmacy Unit, Trento General Hospital, Autonomous Province of Trento,
5
6 Trento, Italy
7
8
9
10

11 **Correspondence to:**

12 Roberto Vespignani, B.Eng.

13 IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”

14 Via P. Maroncelli 40, 47014 Meldola (FC), Italy

15
16
17
18
19
20 Tel.: +39-0543-739100; fax: +39-0543-739151; e-mail: roberto.vespignani@irst.emr.it
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction The use of oral treatments is constantly growing in the area of oncology, raising adherence and safety issues. There is an increasing body of literature highlighting the importance of patient empowerment in the self-management of cancer therapies. Within this scenario, the ONCO-TreC platform was customized and fine-tuned through a prospective multicenter training-validation study in cancer patients treated with oral anticancer drugs.

Methods and analysis This prospective randomized trial was designed to compare the effectiveness of two different strategies, ie, an electronic diary (ONCO-TreC) and a paper diary, for the management of oral cancer treatments in patients with solid and hematological tumors. *Ad hoc* strategies are planned to measure and monitor adherence to treatment and to assess usability and acceptability of the electronic diary. Informed consent will be obtained from all study participants.

Ethics and dissemination This innovative eHealth system is expected to contribute to increasing the adherence to and safety of cancer care, promoting patient empowerment and improving patient-doctor communication. Ethical approval was obtained from Romagna Ethics Committee (CEROM), study ID 2108, prot. n. IRST 100.28 of 10/04/2020. Findings will be disseminated through peer-reviewed journals, conferences and event presentations.

Trial registration number: ClinicalTrials.gov NCT04826458

Keywords

oral anticancer agents; home-based healthcare management; adherence; eHealth; patient empowerment

Strengths and limitations of this study

- This multicenter randomized study is the first to compare the efficacy of an electronic diary with that of standard clinical practice;
- ONCO-TreC is expected to contribute to improving the adherence and safety of cancer care, promoting patient empowerment and patient-doctor communication;
- The limited number of cancer centers involved in the trial could make it difficult to transfer the results to the general population;
- The organizational model that includes the presence of the counsellor may not be applicable to all cancer centers.

INTRODUCTION

The use of oral treatments is constantly increasing in the area of onco-hematology, raising adherence and safety issues.¹⁻⁵ Literature data show that there is enormous variability in adherence, with rates varying between 20% and 100%.⁶ Given that poor adherence can have important consequences in terms of treatment efficacy and toxicity,⁷ the concept of patient empowerment plays a key role in the self-management of therapies.^{8,9}

Several trials have been carried out in recent years to evaluate interventions aimed at improving adherence to oral antineoplastic therapies, eg, educational support, treatment monitoring, pharmacy based and counselling programs, pre-filled pill boxes, and automated voice response systems.⁵ To the best of our knowledge, no randomized trials have shown significant differences between intervention and control groups with respect to primary adherence outcomes. Two non-randomized cohort studies suggested a possible benefit in terms of adherence to oral antineoplastic therapy from their intervention programs with respect to retrospective control groups. In one study, a treatment monitoring program for patients undergoing erlotinib for advanced non small cell lung cancer was associated with significantly higher rates of adherence (as measured by both patient self report ($p=0.042$) and pill count ($p=0.002$)) and disease control ($p=0.037$).¹⁰ In another trial, intensified multidisciplinary pharmaceutical care was associated with significantly higher mean daily adherence rates to oral capecitabine in a small cohort of patients with colorectal and breast cancer ($p=0.029$).¹¹

In clinical practice, a program that includes the presence of a counsellor and the delivery of a paper diary is generally considered an adequate standard of care. Within this context, 2.0 web solutions such as telemedicine, mobile health devices and applications (apps)

1
2
3
4 might be useful to improve adherence to medication and to optimize shared management of
5
6 oral agents between patient and healthcare providers.¹⁰⁻¹⁷
7

8
9 The Center for Communication and Information Technology of Fondazione Bruno
10
11 Kessler (FBK-ICT) in Trento developed a monitoring system based on the TreC (CCC,
12
13 Citizen Clinical Record) platform to deliver mobile health services in different chronic
14
15 diseases, such as asthma, type 1 diabetes and hypertension.^{18,19} The system was
16
17 subsequently adapted for home management and remote monitoring of oral anticancer
18
19 therapy (ONCO-TreC).
20
21

22
23 ONCO-TreC was customized, fine-tuned and validated through a prospective
24
25 multicenter study in cancer patients treated with oral anticancer drugs [Passardi et al.,
26
27 *submitted*].²⁰ Forty patients were enrolled, and adherence to cancer treatment was >86%.
28
29 The ability of the system to measure adherence to treatment was high, with a concordance
30
31 of 97.3% (95 CI: 86.1%-99.9%) between investigator and system pill count. System
32
33 usability and acceptability were also very high. However, the small sample size and
34
35 absence of a control arm did not permit any definitive conclusions to be drawn about the
36
37 efficacy of the system in improving adherence.
38
39
40

41
42 The aim of the present study protocol and its primary endpoint is to compare the
43
44 effectiveness of two different strategies, ie, electronic diary (ONCO-TreC) and paper diary,
45
46 in improving adherence to oral cancer therapy in patients with solid and hematological
47
48 tumors.
49

50
51 Secondary endpoints of the study are as follows: (i) to identify the reasons for non-
52
53 adherence in each group of patients (eg, forgetting to take the pills, side-effects,
54
55 misunderstanding of the prescription); (ii) to describe the satisfaction of patients and
56
57
58
59
60

1
2
3
4 healthcare professionals with the different strategies by means of brief questionnaires and
5 semi-structured interviews; (iii) to evaluate the impact of the lack of therapeutic adherence
6
7 in terms of both costs for medicines and overall healthcare costs (eg, hospitalizations,
8
9 health services, access to Emergency Room).
10
11
12
13
14

15 **METHODS AND ANALYSIS**

16 **Study design and participants**

17
18 The research is a prospective randomized, interventional, non-pharmacological, multicenter
19
20 study on cancer patients receiving anticancer oral treatment.
21
22
23
24
25
26

27 **Inclusion and exclusion criteria**

28
29 Inclusion criteria are defined as follows: adult ≥ 18 years old, either gender; Eastern
30
31 Cooperative Oncology Group performance status (ECOG PS) ≤ 2 ; life expectancy > 12
32
33 weeks according to clinical judgment; patient candidate for treatment with an oral agent
34
35 (adjuvant and advanced settings allowed); good understanding of the Italian language;
36
37 ability to follow study procedures and manage mobile devices after a basic training course,
38
39 at the investigator's discretion; written informed consent.
40
41
42

43
44 Patients receiving an intravenous anticancer treatment as well as experimental drugs will
45
46 be excluded to reduce potential confounding in evaluating the strategies.
47
48
49

50 **Recruitment**

51
52 A total of 124 evaluable patients will be considered. Clinicians will identify potentially
53
54 eligible patients, providing them with all the details pertaining to project participation, and
55
56
57
58
59
60

1
2
3
4 collecting the signed informed consent.
5
6
7

8 9 **Randomization**

10 After being approached for face-to-face screening and enrollment, participants will be
11 randomized to the intervention or control group across sites (1:1 randomization) according
12 to the following arms: A) electronic diary (ONCO-TreC APP); B) paper diary.
13
14
15

16 Patients assigned to the electronic diary group will be equipped with a dedicated APP
17 (ONCO-TreC) and receive specific training on its use.
18
19

20 The researchers in charge of the randomization will not have any influence on the
21 routine care of patients, and participation in the project does not imply any significant
22 adjustment in the standard routine care.
23
24
25
26
27
28

29 30 31 **Patient and public involvement**

32 No patient involved.
33
34
35

36 37 38 **ONCO-TreC**

39 ONCO-TreC consists of a mobile application (APP) delivered to patients and a web-based
40 dashboard managed by healthcare professionals. The APP contains a visual reminder of
41 cancer therapy, a simplified adverse event reporting system, a section for vital signs
42 entering, and a messaging system. Clinicians enter the details of oral treatment schedules
43 through the dashboard, set reminders, monitor for adherence to treatment and reported
44 adverse events, and can communicate with patients through the messaging system. A
45 detailed description of the ONCO-TreC has been reported elsewhere.²⁰
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Counsellor

Patients of both arms will be followed by a trained healthcare professional (counsellor) who will be responsible for drug and diary delivery. The counsellor will also train the patient and/or caregiver at the very first treatment cycle with regard to (i) therapy (dosage, duration, storage methods, etc.) and (ii) issues/adverse events reporting. The healthcare staff will instruct the patient to return all the drug packs received, even if empty, at each cycle, for pill count. In addition, the counsellor will obtain information from patients about any concomitant drugs used at home. All these procedures will take place inside an adequate and dedicated room.

Study procedures

At the baseline visit, demographic data (age, sex, educational qualification and occupation), cancer history, and information on concomitant diseases and therapies will be collected; physical examination with vital signs and performance status assessment will be carried out. Patients assigned to arm A will be provided with the ONCO-TreC APP (installed on a smartphone or tablet), the oral drug for a treatment cycle and an appointment for the next cycle, and will be instructed on how to use the APP. Patients assigned to arm B will be provided with a paper diary, the oral medication and an appointment for the next cycle, and will be given instructions on how to use the paper diary.

During the patient's medical visits at each treatment cycle, adherence and adverse events will be reported in the patient's medical records, as per clinical practice. In addition, at each cycle the counsellor will check the patient's diary (paper or electronic), count any remaining tablets, and evaluate the need for retraining. Patients will also receive the drug

1
2
3
4 supply for a new treatment cycle, the appointment for the next cycle and, for those in arm
5
6 B, a new paper diary.
7

8
9 The evaluation period will end after 6 cycles of therapy or before in the event of a
10
11 change of therapy (for disease progression or unacceptable toxicity) or patient refusal. Each
12
13 patient, once the planned 6-cycle phase is over, will continue the treatment, with visits and
14
15 procedures as per clinical practice.
16

17
18 Usability and acceptability of ONCO-TreC and paper diary by patients will be assessed
19
20 through 3 questionnaires: Q-pre and Q-post at baseline and at the end of observation (EoO);
21
22 and the Italian version of the System Usability Scale (SUS) at EoO.²¹ Q-pre and Q-post are
23
24 *ad hoc* questionnaires developed to analyze patient expectations with regard to the system
25
26 (Q-pre) and to evaluate system acceptability (Q-post) and communication between patients
27
28 and cancer centers (Q-pre and Q-post). A subgroup of patients will also undergo semi-
29
30 structured interviews by FBK-ICT sociologists at EoO. These interviews will be conducted
31
32 by teleconference and will focus on healthcare practice and the use of the electronic or
33
34 paper diary. FBK-ICT sociologists will also conduct semi-structured interviews with the
35
36 oncologists, counsellors and healthcare professionals involved in the trial to evaluate the
37
38 impact of the technology on the workload, as well as patient-hospital communication,
39
40 adherence and adverse events management.
41
42
43
44
45
46
47

48 **Data management**

49
50 ONCO-TreC APP will communicate with a back-end service to store data on a central
51
52 server. Researchers will be able to evaluate capability data through a web-based dashboard.
53

54
55 Data entered into the system or paper diary by the patient will be compared with those
56
57
58
59
60

1
2
3
4 assessed by the oncologist and/or the counsellor. In particular, the adherence to treatment
5 that emerges from diaries will be related to the number of residual pills returned during the
6 hospital visit, and adverse events reported in the diaries will be compared to those reported
7 to the oncologist and recorded in the medical records. Data will be registered in electronic
8 case report forms, implemented using a relational database management system and a
9 graphic user interface.
10
11
12
13
14
15
16
17
18
19

20 **Statistical Analysis**

21
22 Adherence will be assessed at each treatment cycle by counting the remaining pills. Any
23 patient who takes at least 90% of the total planned drug dose as per study protocol will be
24 defined as adherent. Patients who take fewer tablets than prescribed due to toxicity or
25 medical decision will be considered adherent if this decision is recorded in the medical
26 records. The effectiveness of each experimental strategy will be evaluated by comparing
27 the proportion of adherent patients in the corresponding groups.
28
29
30
31
32
33
34
35

36 Patient perception about ONCO-TreC or paper diary will be assessed through
37 questionnaires. Two specific questionnaires (Q-pre, Q-post) will be administered to
38 evaluate patient expectations about the system, system acceptability, quality of care and
39 patient-doctor communication. An internationally validated SUS will be used to investigate
40 system usability in the experimental arm. The semi-structured interviews will be audio-
41 recorded, transcribed and assessed by the template analysis, a structured technique for the
42 evaluation of qualitative data.
43
44
45
46
47
48
49
50
51

52 The sample size was calculated assuming a percentage of non-adherence to oral therapy
53 of 40% in arm B, and a 60% reduction in the percentage of non-adherent patients in arm A.
54
55
56
57
58
59
60

1
2
3
4 A sample consisting of 124 patients (62 patients for each arm) will provide 80% power to
5
6 identify an absolute difference greater than 24 percentage points using a bilateral Fisher's
7
8 exact test with a significance level of 0.05. Considering a dropout rate of 10%,
9
10 approximately 136 total patients will have to be enrolled.
11

12
13 The hypothesis relating to the primary endpoint of the study will be tested using Fisher's
14
15 exact test. The percentage of adherent patients in the 2 groups will be reported both as a
16
17 point estimate and by means of 95% confidence intervals. Secondary endpoints will be
18
19 reported through descriptive statistics: mean \pm standard deviation (sd) or median and
20
21 interquartile range for continuous variables, and absolute and relative frequency for
22
23 categorical variables.
24
25
26
27
28

29 **ETHICS AND DISSEMINATION**

30
31 This Italian multicenter randomized study, approved by the Romagna Ethics Committee
32
33 (CEROM), study ID 2108, prot. n. IRST 100.28 of 10/04/2020, will be conducted in
34
35 accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines.
36
37 Informed consent will be obtained from all individual study participants before enrollment.
38
39

40
41 Considering the impact of adherence to oral treatments in onco-hematology in terms of
42
43 treatment efficacy and toxicity, the validation of reliable and easy-to-use tools to improve
44
45 patients' self-management of therapies is essential.⁹ Current literature supports the idea that
46
47 multilayer approaches including educational support, treatment monitoring, pharmacy
48
49 based and counselling programs are essential for improving adherence and, therefore,
50
51 treatment efficacy.⁵ An increasing level of acceptance to m-health technologies in oncology
52
53 is being shown by patients and healthcare staff. However, despite the numerous studies
54
55
56
57
58
59
60

1
2
3
4 published on this issue, there is still a clear need to further promote the validation of
5
6 technological, organizational and m-health platforms (eg, APP) to support patients' self-
7
8 management, which is a key factor in sustaining proper treatment adherence.
9

10
11 The present multicenter randomized study represents a unique contribution in this area
12
13 in that it will be the first to compare the efficacy of an electronic diary with that of standard
14
15 clinical practice. The technological platform adopted, ONCO-TreC, evaluated in a previous
16
17 study,²⁰ is expected to contribute to further improving the adherence and safety of cancer
18
19 care, and promoting patient empowerment and patient-doctor communication. In addition,
20
21 the involvement of different stakeholders (eg, healthcare institutions, research centers)
22
23 represents a key element in ensuring a correct evaluation of the present trial. A specific
24
25 evaluation component has been designed to correctly assess the implementation of the
26
27 technological platform and the organizational aspects behind it. At the same time, the study
28
29 also has a number of limitations. The first concerns the small number of cancer centers
30
31 involved in the trial, which could arguably restrict the generalizability of results. Secondly,
32
33 the study design has been carefully adapted to the specific organizational contexts in which
34
35 the research will take place. Although this could represent a strength of the project in terms
36
37 of feasibility, an organizational model where a pharmacist counsellor plays a key role may
38
39 not be applicable or reproducible in all cancer centers.
40
41
42
43
44

45
46 The present trial holds great promise for substantially impacting and benefitting a large
47
48 audience. The results will be disseminated through peer-reviewed journals, conferences and
49
50 event presentations.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Acknowledgements:** The authors would like to acknowledge all their colleagues from the
5
6 different institutions who contributed to the study protocol.
7
8
9

10
11 **Contributors:** All authors participated in the design of the study and its organization and
12
13 implementation. The first draft of the manuscript was jointly written by AP and LG. All
14
15 authors contributed to editing subsequent drafts and all read and approved the final
16
17 manuscript for submission.
18
19

20
21
22 **Funding:**

23
24 This research received no specific grant from any funding agency in the public, commercial
25
26 or not-for-profit sectors.
27
28
29

30
31 **Competing interests:** None declared.
32
33

34
35
36 **Ethical statement:** This study was approved Ethical approval was obtained from Romagna
37
38 Ethics Committee (CEROM), study ID 2108, prot. n. IRST 100.28 of 10/04/2020, will be
39
40 conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice
41
42 guidelines. Informed consent will be obtained from all individual study participants before
43
44 enrollment.
45
46
47

48
49
50 **Data availability:** Data sharing is not applicable to this article as no new data were created
51
52
53 or analyzed.
54
55
56
57

REFERENCES

- 1 Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med* 2005;353:487-97.
- 2 Brown MT, Bussell JK. Medication adherence: WHO cares? *Mayo Clin Proc* 2011;86:304-14.
- 3 Huang WC, Chen CY, Lin SJ, *et al.* Medication adherence to oral anticancer drugs: systematic review. *Expert Rev Anticancer Ther* 2016;16:423-32.
- 4 Bergsbaken JJ, Eickhoff JC, Buss BA, *et al.* Assessment of adherence with oral anticancer agents in oncology clinical trials: A systematic review. *J Oncol Pharm Pract* 2016;22:105-13.
- 5 Greer JA, Amoyal N, Nisotel L, *et al.* A Systematic Review of Adherence to Oral Antineoplastic Therapies. *Oncologist* 2016;21:354-76.
- 6 Fenerty SD, West C, Davis SA, *et al.* The effect of reminder systems on patients' adherence to treatment. *Patient Prefer Adherence* 2012;6:127-35.
- 7 Vervloet M, van Dijk L, Santen-Reestman J, *et al.* SMS reminders improve adherence to oral medication in type 2 diabetes patients who are real time electronically monitored. *Int J Med Inform* 2012;81:594-604.
- 8 Oakley C, Lennan E, Roe H, *et al.* Safe practice and nursing care of patients receiving oral anti-cancer medicines: a position statement from UKONS. *Ecancermedicalscience* 2010;4:177.
- 9 Mathes T, Antoine SL, Pieper D, *et al.* Adherence enhancing interventions for oral anticancer agents: a systematic review. *Cancer Treat Rev* 2014;40:102-8.
- 10 Gebbia V, Bellavia M, Banna GL, *et al.* Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung

- cancer. *Clin Lung Cancer* 2013;14:390-8.
- 11 Simons S, Ringsdorf S, Braun M, *et al.* Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. *Support Care Cancer* 2011;19:1009-18.
- 12 Weaver A, Young AM, Rowntree J, *et al.* Application of mobile phone technology for managing chemotherapy-associated side-effects. *Ann Oncol* 2007;18:1887-92.
- 13 Paré G, Moqadem K, Pineau G, *et al.* Clinical effects of home telemonitoring in the context of diabetes, asthma, heart failure and hypertension: a systematic review. *J Med Internet Res* 2010;12:e21.
- 14 Polisen J, Tran K, Cimon K, *et al.* Home telehealth for chronic obstructive pulmonary disease: a systematic review and meta-analysis. *J Telemed Telecare* 2010;16:120-7.
- 15 Polisen J, Tran K, Cimon K, *et al.* Home telemonitoring for congestive heart failure: a systematic review and meta-analysis. *J Telemed Telecare* 2010;16:68-76.
- 16 Galligioni E, Piras EM, Galvagni M, *et al.* Integrating mHealth in Oncology: Experience in the Province of Trento. *J Med Internet Res* 2015;17:e114.
- 17 Galligioni E, Berloff F, Caffo O, *et al.* Development and daily use of an electronic oncological patient record for the total management of cancer patients: 7 years' experience. *Ann Oncol* 2009;20:349-52.
- 18 Eccher C, Gios L, Zanutto A, *et al.* TreC platform. An integrated and evolving care model for patients' empowerment and data repository. *J Biomed Inform* 2020;102:103359.
- 19 Eccher C, Piras EM, Stenico M. TreC - a REST-based regional PHR. *Stud Health Technol Inform* 2011;169:108-12.

- 1
2
3
4 20 Passardi A, Rizzo M, Maines F, *et al.* Optimisation and validation of a remote
5
6 monitoring system (Onco-TreC) for home-based management of oral anticancer
7
8 therapies: an Italian multicentre feasibility study. *BMJ Open* 2017;7:e014617.
9
10
11 21 Brooke, J. SUS: A “quick and dirty” usability scale. In: Jordan PW, Thomas B,
12
13 Weerdmeester BA, editors. *Usability Evaluation in Industry*. London: Taylor & Francis;
14
15 1996:189-94.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Use of the ONCO-TreC electronic diary compared with a standard paper diary to improve adherence to oral cancer therapy in patients with solid and hematological tumors: protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055814.R1
Article Type:	Protocol
Date Submitted by the Author:	12-Nov-2021
Complete List of Authors:	<p>Passardi, Alessandro; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Department of Medical Oncology Serra, Patrizia; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Unit of Biostatistic and Clinical Trials Caffo, Orazio; Provincia autonoma di Trento Azienda Provinciale per i Servizi Sanitari, Department of Medical Oncology Masini, Carla; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Oncology Pharmacy Unit Brugugnoli, Erika; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Oncology Pharmacy Unit Vespignani, Roberto; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, IT Service Giardino, Valeria; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Unit of Biostatistics and Clinical Trials Petracci, Elisabetta ; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Unit of Biostatistics and Clinical Trials Bartolini, Giulia; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Department of Medical Oncology Sullo, Francesco; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Department of Medical Oncology Anesi, Cecilia; Provincia autonoma di Trento Azienda Provinciale per i Servizi Sanitari, Department of Medical Oncology Dianti, Marco; Bruno Kessler Foundation, eHealth Unit Eccher, Claudio; Bruno Kessler Foundation, eHealth Unit Piras, Enrico; Bruno Kessler Foundation, eHealth Unit Gios, Lorenzo; TrentinoSalute 4.0, Competence Center for Digital Health Campomori, Annalisa; Presidio Ospedaliero Santa Chiara, Hospital Pharmacy Unit Oberosler, Valentina; Presidio Ospedaliero Santa Chiara, Hospital Pharmacy Unit Forti, Stefano; Bruno Kessler Foundation, eHealth Unit</p>
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Health informatics, Haematology (incl blood transfusion)
Keywords:	Information management < BIOTECHNOLOGY & BIOINFORMATICS,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	ONCOLOGY, ORAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 Original research
5
6
7 2
8

9 3 **Use of the ONCO-TreC electronic diary compared with a**
10 **standard paper diary to improve adherence to oral cancer**
11 **therapy in patients with solid and hematological tumors:**
12 **protocol for a randomized controlled trial**
13
14
15
16
17
18
19
20
21
22

23 8 Alessandro Passardi,¹ Patrizia Serra,² Orazio Caffo,³ Carla Masini,⁴ Erika Brugugnoli,⁴
24
25 9 Roberto Vespignani,⁵ Valeria Giardino,² Elisabetta Petracci,² Giulia Bartolini,¹ Francesco
26
27 10 Sullo,¹ Cecilia Anesi,³ Marco Dianti,⁶ Claudio Eccher,⁶ Enrico Maria Piras,⁶ Lorenzo Gios,⁷
28
29 11 Annalisa Campomori,⁸ Valentina Oberosler,⁸ Stefano Forti⁶
30
31
32
33
34

35 13 ¹ Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori
36
37 14 (IRST) “Dino Amadori”, Meldola, Italy
38

39 15 ² Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei
40
41 16 Tumori (IRST) “Dino Amadori”, Meldola, Italy
42
43

44 17 ³ Department of Medical Oncology, Azienda Provinciale per i Servizi Sanitari, Trento, Italy
45

46 18 ⁴ Oncology Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)
47
48 19 “Dino Amadori”, Meldola, Italy
49

50
51 20 ⁵ IT Service, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”,
52
53 21 Meldola, Italy
54
55
56
57
58
59
60

1
2
3
4 22 ⁶ Center for Information and Communication Technology, eHealth Unit, Fondazione
5

6
7 23 “Bruno Kessler”, Trento, Italy
8

9 24 ⁷ TrentinoSalute 4.0, Competence Center for Digital Health, Trento, Italy
10

11 25 ⁸ Hospital Pharmacy Unit, Trento General Hospital, Autonomous Province of Trento,
12
13 Trento, Italy
14
15

16 27

17
18 28 **Correspondence to:**

19
20 29 Roberto Vespignani, B.Eng.

21
22 30 IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”
23

24
25 31 Via P. Maroncelli 40, 47014 Meldola (FC), Italy
26

27 32 Tel.: +39-0543-739100; fax: +39-0543-739151; e-mail: roberto.vespignani@irst.emr.it
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

33 **ABSTRACT**

34 **Introduction** ONCO-TreC platform consists of a mobile application delivered to patients
35 as electronic diary and a web-based dashboard managed by healthcare professionals. We
36 aim to compare the effectiveness of ONCO-TreC electronic diary with a standard paper
37 diary, in improving adherence to oral cancer therapy in patients with solid and
38 haematological tumors.

39 **Methods and analysis** This is an open label, superiority, randomised controlled trial
40 conducted in 2 Italian Oncology Units. Patients will be randomized with a 1:1 ratio to
41 electronic or paper diary. For both groups a counsellor will be responsible for drug and
42 diary delivery. The evaluation period will end after 6 cycles of therapy. The primary aim is
43 to compare the proportion of non-adherent patients in the two arms. Adherence will be
44 measured through pill count; anyone who takes less than 90% of the total prescribed drug
45 dose will be considered non-adherent. Assuming a percentage of non-adherent patients to
46 oral therapy of 40% in arm B, and a 60% reduction in this percentage in arm A, a sample of
47 124 patients will provide 80% power to identify an absolute difference greater than 24
48 percentage points using a bilateral Fisher's exact test with a significance level of 0.05.
49 Considering a dropout rate of 10%, approximately 136 patients will have to be enrolled.
50 The primary analysis will be performed on the intention-to-treat population. Secondary
51 aims are to describe the reasons for non-adherence, the level of satisfaction of patients and
52 healthcare professionals with the paper and electronic diary, and the impact of non-
53 adherence in terms of healthcare costs.

54 **Ethics and dissemination** Ethical approval was obtained from Romagna Ethics Committee
55 (CEROM), study ID 2108, prot. n. IRST 100.28 of 10/04/2020. Informed consent will be

1
2
3
4 56 obtained from all study participants. Findings will be disseminated through peer-reviewed
5
6
7 57 journals, conferences and event presentations.
8
9
10 58

11 59 **Protocol version:** V.2, 6 April 2021

12
13 60 **Trial registration number:** ClinicalTrials.gov NCT04826458
14
15
16 61

17 18 62 **Keywords**

19
20 63 oral anticancer agents; home-based healthcare management; adherence; eHealth; patient
21
22 64 empowerment
23
24
25 65

26 27 66 **Strengths and limitations of this study**

- 28
29
30 67 • This multicenter randomized study is the first to compare the efficacy of an electronic
31
32 68 diary with that of standard clinical practice.
33
34 69 • The majority of cancer patients use smart phones or tablets on a regular basis.
35
36
37 70 • Methodological strengths include sample size and randomization, rigorous
38
39 71 measurement of adherence, wide qualitative data deriving from questionnaires and semi
40
41 72 structured interviews.
42
43
44 73 • The limited number of cancer centers involved in the trial could make it difficult to
45
46 74 generalize the results to the general population.
47
48 75 • The organizational model that includes the presence of the counsellor may not be
49
50 76 applicable to all cancer centers.
51
52
53
54
55
56
57
58
59
60

77 INTRODUCTION

78 The use of oral treatments is constantly increasing in the area of onco-hematology, raising
79 adherence and safety issues.¹⁻⁵ Literature data show that there is enormous variability in
80 adherence, with rates varying between 20% and 100%.⁶ Given that poor adherence can
81 have important consequences in terms of treatment efficacy and toxicity,⁷ the concept of
82 patient empowerment plays a key role in the self-management of therapies.^{8,9}

83 Several trials have been carried out in recent years to evaluate interventions aimed at
84 improving adherence to oral antineoplastic therapies, eg, educational support, counselling
85 programs, pre-filled pill boxes, and automated voice response systems.⁵ To the best of our
86 knowledge, no randomized trials have been performed to evaluate the difference between
87 intervention and control groups with respect to primary adherence outcomes. Two non-
88 randomized cohort studies showed a benefit in terms of adherence to oral antineoplastic
89 therapy from their intervention programs with respect to retrospective control groups. In
90 one study, a treatment monitoring program, where the patient and the caregiver were
91 extensively informed about drug characteristics and potential side effects and trained in
92 their management, was provided to patients undergoing erlotinib for advanced non small
93 cell lung cancer; this intervention was associated with significantly higher rates of
94 adherence - as measured by both patient self report ($p=0.042$) and pill count ($p=0.002$) -
95 and disease control ($p=0.037$).¹⁰ In another trial, intensified multidisciplinary
96 pharmaceutical care was associated with significantly higher mean daily adherence rates to
97 oral capecitabine in a small cohort of patients with colorectal and breast cancer ($p=0.029$).¹¹

98 In clinical practice, a program that includes the presence of a counsellor and the delivery
99 of a paper diary is generally considered an adequate standard of care. Within this context,

1
2
3
4 100 2.0 web solutions such as telemedicine, mobile health devices and applications (apps)
5
6 101 might be useful to improve adherence to medication and to optimize shared management of
7
8
9 102 oral agents between patient and healthcare providers.¹⁰⁻¹⁷

10
11 103 The Center for Communication and Information Technology of Fondazione Bruno
12
13 104 Kessler (FBK-ICT) in Trento developed a monitoring system based on the TreC (CCC,
14
15 105 Citizen Clinical Record) platform to deliver mobile health services in different chronic
16
17 106 diseases, such as asthma, type 1 diabetes and hypertension.^{18,19} The system was
18
19 107 subsequently adapted for home management and remote monitoring of oral anticancer
20
21 108 therapy (ONCO-TreC).

22
23
24 109 ONCO-TreC was customized, fine-tuned and validated through a prospective
25
26 110 multicenter study in cancer patients treated with oral anticancer drugs.²⁰ Forty patients were
27
28 111 enrolled, and adherence to cancer treatment was >86%. The ability of the system to
29
30 112 measure adherence to treatment was high, with a concordance of 97.3% (95 CI: 86.1%-
31
32 113 99.9%) between investigator and system pill count. System usability and acceptability were
33
34 114 also very high. However, the small sample size and absence of a control arm did not permit
35
36 115 any definitive conclusions to be drawn about the efficacy of the system in improving
37
38 116 adherence [Passardi et al., *submitted*].

39
40
41 117 The aim of the present study is to compare the effectiveness of two different strategies,
42
43 118 ie, electronic diary and paper diary, in improving adherence to oral cancer therapy in
44
45 119 patients with solid and hematological tumors.

46
47
48 120

49
50
51 121

52
53
54 122

123 **METHODS AND ANALYSIS**

124 **Study design and participants**

125 The research is an Italian prospective open label, superiority, randomized, interventional,
126 non-pharmacological, multicenter clinical study on cancer patients receiving anticancer oral
127 treatment.

128

129 **Inclusion and exclusion criteria**

130 Inclusion criteria are defined as follows: adult ≥ 18 years old, either gender; Eastern
131 Cooperative Oncology Group performance status (ECOG PS) ≤ 2 ; life expectancy > 12
132 weeks according to clinical judgment; patient candidate for treatment with an oral agent
133 (adjuvant and advanced settings allowed); good understanding of the Italian language;
134 ability to follow study procedures and manage mobile devices after a basic training course,
135 at the investigator's discretion; written informed consent.

136 Patients receiving an intravenous anticancer treatment as well as experimental drugs will
137 be excluded to reduce potential confounding in evaluating the strategies.

138

139 **Recruitment**

140 This study will be jointly conducted at 2 Italian cancer care and research centers: IRCCS
141 Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola; Oncology
142 Unit of the Azienda Provinciale per i Servizi Sanitari (APSS) in Trento. Clinicians will
143 identify potentially eligible patients, providing them with all the details pertaining to
144 project participation, and collecting the signed informed consent. Recruitment started in
145 May 2021 and is expected to last 24 months. Total study duration is 36 months.

146 **Randomization**

147 After being approached for face-to-face screening and enrollment, participants will be
148 randomized to the intervention or control group across sites (1:1 ratio), according to the
149 following arms: A) electronic diary (ONCO-TreC APP); B) paper diary. A permuted block
150 unstratified randomization procedure, with block sizes randomly varying between 4 and 6,
151 will be used. The randomization sequence will be computer-generated by the Biostatistics
152 and Clinical Trials Unit of IRST and implemented using centralized controlled website
153 randomization service and electronic data capture system (OpenClinica V.3.12.2). The
154 investigators will not have access to the randomization list.

155 Patients assigned to the electronic diary group will be equipped with a dedicated APP
156 (ONCO-TreC) and receive specific training on its use. The researchers in charge of the
157 randomization will not have any influence on the routine care of patients, and participation
158 in the project does not imply any significant adjustment in the standard routine care.

160 **Patient and public involvement**

161 No patient involved.

163 **ONCO-TreC and paper diary**

164 ONCO-TreC consists of a mobile application (APP) delivered to patients and a web-based
165 dashboard managed by healthcare professionals. The APP contains a visual reminder of
166 cancer therapy, a simplified adverse event reporting system, a section for vital signs
167 entering, and a messaging system. Clinicians enter the details of oral treatment schedules

1
2
3
4 168 through the dashboard, set reminders, monitor for adherence to treatment and reported
5
6 169 adverse events, and can communicate with patients through the messaging system. A
7
8
9 170 detailed description of the ONCO-TreC has been reported elsewhere.²⁰
10

11 171 Each study center will provide patients in the control arm with a paper diary according
12
13 172 to clinical practice. This diary must contain some essential information, e.g. drug name,
14
15 173 dosage, dates of administration. There is also a section for reporting any side effects and
16
17 174 notes.
18
19

20 175

22 176 **Counsellor**

23
24
25 177 Patients of both arms will be followed by a trained healthcare professional (counsellor) who
26
27 178 will be responsible for drug and diary delivery. The counsellor will also train the patient
28
29 179 and/or caregiver at the very first treatment cycle with regard to (i) therapy (dosage,
30
31 180 duration, storage methods, etc.) and (ii) issues/adverse events reporting. The healthcare
32
33 181 staff will instruct the patient to return all the drug packs received, even if empty, at each
34
35 182 cycle, for pill count. In addition, the counsellor will obtain information from patients about
36
37 183 any concomitant drugs used at home. All these procedures will take place inside an
38
39 184 adequate and dedicated room.
40
41
42

43 185

45 186 **Study procedures**

46
47
48 187 At the baseline visit, demographic data (age, sex, educational qualification and occupation),
49
50 188 cancer history, and information on concomitant diseases and therapies will be collected;
51
52 189 physical examination with vital signs and performance status assessment will be carried
53
54
55 190 out. Patients assigned to arm A will be provided with the ONCO-TreC APP (installed on a
56
57
58
59
60

1
2
3
4 191 smartphone or tablet), the oral drug for a treatment cycle and an appointment for the next
5
6 192 cycle, and will be instructed on how to use the APP. Patients assigned to arm B will be
7
8
9 193 provided with a paper diary, the oral medication and an appointment for the next cycle, and
10
11 194 will be given instructions on how to use the paper diary.

12
13 195 During the patient's medical visits at each treatment cycle, adherence and adverse events
14
15 196 will be reported in the patient's medical records, as per clinical practice. In addition, at each
16
17 197 cycle the counsellor will check the patient's diary (paper or electronic), count any
18
19 198 remaining tablets, and evaluate the need for retraining. Patients will also receive the drug
20
21 199 supply for a new treatment cycle, the appointment for the next cycle and, for those in arm
22
23 200 B, a new paper diary.

24
25
26
27 201

28 29 202 **Outcome measures**

30
31 203 The primary outcome of the trial is to compare the proportion of non-adherent patients in
32
33 204 the experimental and control arms. Adherence will be assessed at each treatment cycle by
34
35 205 counting the remaining pills. Any patient who takes less than 90% of the total planned drug
36
37 206 dose during the study period as per study protocol will be defined as non-adherent. Patients
38
39 207 who take fewer tablets than prescribed due to toxicity or medical decision will be
40
41 208 considered adherent if this decision is recorded in the medical records. The evaluation
42
43 209 period will end after 6 cycles of therapy or earlier due to a therapy change for disease
44
45 210 progression or unacceptable toxicity or patient refusal. Each patient, once the planned 6-
46
47 211 cycle phase is over, will continue the treatment, with visits and procedures as per clinical
48
49 212 practice.

50
51 213 As for the secondary aims, the reasons for non-adherence (eg, forgetting to take the pills,
52
53
54

1
2
3
4 214 side-effects, misunderstanding of the prescription) will be registered in the medical records
5
6 215 by the counselor during each cycle visit and summarized through percentages (ie.
7
8
9 216 percentage of non-adherent patients by cause and study arm).

10
11 217 Usability and acceptability of ONCO-TreC and paper diary by patients will be assessed
12
13 218 through 3 questionnaires: Q-pre and Q-post administered at baseline and at the end of
14
15 219 observation (EoO); and the Italian version of the System Usability Scale (SUS) at EoO.²¹
16
17 220 Q-pre and Q-post are *ad hoc* questionnaires developed to analyze patient expectations with
18
19 221 regard to the system (Q-pre) and to evaluate system acceptability (Q-post) and
20
21 222 communication between patients and cancer centers (Q-pre and Q-post) through 4-point
22
23 223 Likert scale questions as well as open-ended questions. Answers will be reported in terms
24
25 224 of percentages. The data from SUS questionnaire will be summarized by first summing, for
26
27 225 each patient, the score contributions from each item. For items 1, 3, 5, 7, and 9 the score
28
29 226 contribution is given by subtracting 1 to the scale position. For items 2, 4, 6, 8, and 10, the
30
31 227 contribution is 5 minus the scale position. Then, multiplying by 2.5 the sum of the score
32
33 228 contributions. The overall system usability level will be averaged over all patients
34
35 229 randomized to Arm A.

36
37
38
39 230 A subgroup of patients will also undergo semi-structured interviews by FBK-ICT
40
41 231 sociologists at EoO. These interviews will be conducted by teleconference and will focus
42
43 232 on healthcare practice and the use of the electronic or paper diary. FBK-ICT sociologists
44
45 233 will also conduct semi-structured interviews with the oncologists, counsellors and
46
47 234 healthcare professionals involved in the trial to evaluate the impact of the technology on the
48
49 235 workload, as well as patient-hospital communication, adherence and adverse events
50
51 236 management. The semi-structured interviews will be audio-recorded, transcribed and
52
53
54
55
56
57
58
59
60

1
2
3
4 237 assessed by the template analysis, a structured technique for the evaluation of qualitative
5
6 238 data.

7
8
9 239 The costs for medicines and for hospital resource utilization (eg, hospitalizations, access
10
11 240 to the emergency room) will be assessed for patients enrolled at IRST and resident in the
12
13 241 Emilia-Romagna Region only. Administrative sources such as the pharmacy dispensing
14
15 242 database, hospital discharge cards, and the outpatient specialist assistance services database
16
17 243 will be considered. The costs for healthcare procedures will be measured according to the
18
19 244 regional Healthcare Range of Outpatients Fees, in order to estimate the cost actually
20
21 245 incurred by the healthcare provider, while for inpatient setting, we will compute the entire
22
23 246 DRG (Diagnosis Related Group)-related costs. Unit costs for drugs will be acquired from
24
25 247 the national pharmaceutical formulary drafted by the Italian Medicines Agency (AIFA).
26
27 248 Costs will be assessed on a per-patient per-month (PPPM) basis and summarized as
28
29 249 follows: (total amount of costs from the start of intervention start until its end/days from the
30
31 250 start of intervention until its end) \times 30.
32
33
34
35
36
37
38

39 252 **Data management**

40
41 253 ONCO-TreC APP will communicate with a back-end service to store data on a central
42
43 254 server. Researchers will be able to evaluate capability data through a web-based dashboard.
44
45 255 Data entered into the system or paper diary by the patient will be compared with those
46
47 256 assessed by the oncologist and/or the counsellor. In particular, the adherence to treatment
48
49 257 that emerges from diaries will be related to the number of residual pills returned during the
50
51 258 hospital visit, and adverse events reported in the diaries will be compared to those reported
52
53 259 to the oncologist and recorded in the medical records. Data will be registered in electronic
54
55
56
57
58
59
60

260 case report forms, implemented using a relational database management system and a
261 graphic user interface (OpenClinica V.3.12.2).

262

263 **Statistical Analysis**

264 The sample size was calculated assuming a percentage of non-adherence to oral therapy of
265 40% in arm B, and a 60% reduction in the percentage of non-adherent patients in arm A. A
266 sample consisting of 124 patients (62 patients for each arm) will provide 80% power to
267 identify an absolute difference greater than 24 percentage points using a bilateral Fisher's
268 exact test with a significance level of 0.05. Considering a dropout rate of 10%,
269 approximately 136 total patients will have to be enrolled.

270 The main study hypothesis will be tested using Fisher's exact test. The percentage of
271 non-adherent patients in the 2 groups will be reported both as a point estimate and by
272 means of 95% confidence intervals in the intention-to-treat population. Secondary
273 outcomes will be reported through descriptive statistics: mean \pm standard deviation (sd) or
274 median and interquartile range for continuous variables, and absolute and relative
275 frequency for categorical variables. Such descriptive statistics will be computed on the
276 overall population, by patient randomization arm, and other clinical characteristics, as
277 appropriate.

278

279 **ETHICS AND DISSEMINATION**

280 This Italian multicenter randomized study, approved by the Romagna Ethics Committee
281 (CEROM), study ID 2108, prot. n. IRST 100.28 of 10/04/2020, will be conducted in
282 accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines.

1
2
3
4 283 Informed consent will be obtained from all individual study participants before enrollment.
5

6 284 The results will be disseminated through peer-reviewed journals, conferences and event
7
8
9 285 presentations. All information and documentation provided to investigators are considered
10
11 286 confidential and cannot be given or disclosed to third parties. The investigators will prepare
12
13 287 and maintain adequate and accurate source documents designed to record all observations
14
15 288 and other pertinent data for each patient. Only the study promoter staff will have access to
16
17 289 the final dataset containing pseudonymized data.
18
19

20 290 Any study modification will be notified to the pertinent Ethics Committee through an
21
22 291 amendment.
23
24

25 292

27 293 **DISCUSSION**

28
29 294 Considering the impact of adherence to oral treatments in onco-hematology in terms of
30
31 295 treatment efficacy and toxicity, the validation of reliable and easy-to-use tools to improve
32
33 296 patients' self-management of therapies is essential.⁹ Current literature supports the idea that
34
35 297 multilayer approaches including educational support, treatment monitoring, pharmacy
36
37 298 based and counselling programs are essential for improving adherence and, therefore,
38
39 299 treatment efficacy.⁵ An increasing level of acceptance to m-health technologies in oncology
40
41 300 is being shown by patients and healthcare staff. However, despite the numerous studies
42
43 301 published on this issue, there is still a clear need to further promote the validation of
44
45 302 technological, organizational and m-health platforms (eg, APP) to support patients' self-
46
47 303 management, which is a key factor in sustaining proper treatment adherence²².
48
49

50
51 304 The present multicenter randomized study represents a unique contribution in this area
52
53 305 in that it will be the first to compare the efficacy of an electronic diary with that of standard
54
55
56
57
58
59
60

1
2
3
4 306 clinical practice. Nowadays, the majority of cancer patients, even the elderly, use smart
5
6 307 phones or tablets on a regular basis. The technological platform adopted, ONCO-TreC,
7
8 308 evaluated in a previous study,²⁰ is expected to contribute to further improving the adherence
9
10 309 and safety of cancer care, and promoting patient empowerment and patient-doctor
11
12 310 communication. The methodological strengths of the present trial include the sample size
13
14 311 and randomization of patients, a rigorous measurement of adherence, and the analysis of
15
16 312 qualitative data deriving from questionnaires and semi structured interviews. In addition,
17
18 313 the involvement of different stakeholders (eg, healthcare institutions, research centers)
19
20 314 represents a key element in ensuring a correct evaluation of the present trial. At the same
21
22 315 time, the study also has a number of limitations. The first concerns the small number of
23
24 316 cancer centers involved in the trial, which could arguably restrict the generalizability of
25
26 317 results. Secondly, the study design has been carefully adapted to the specific organizational
27
28 318 contexts in which the research will take place. Although this could represent a strength of
29
30 319 the project in terms of feasibility, an organizational model where a pharmacist counsellor
31
32 320 plays a key role may not be applicable or reproducible in all cancer centers.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 321 **Acknowledgements:** The authors would like to acknowledge all their colleagues from the
8
9 322 different institutions who contributed to the study protocol.

10
11 323 **Contributors:** PS, AP, RV and SF conceived the idea for the study; AP, PS, RV, CM, OC,
12
13 324 EP and SF designed the study; AP, EMP and PS took care of questionnaires and semi
14
15 325 structured interviews; RV, CE and MD contributed to ONCO-TreC fine-tuning and
16
17 326 implementations; CM, AC, EB and VB contributed to the definition of roles and
18
19 327 responsibilities of the counselor; VG, GB, FS and CA critically reviewed and revised the
20
21 328 protocol drafts; EP performed the statistical analyses. The first draft of the manuscript was
22
23 329 jointly written by AP, EP and LG. All authors participated in the organization of the study.
24
25
26 330 All authors contributed to editing subsequent drafts and all read and approved the final
27
28 331 manuscript for submission.

29
30
31
32 332 **Ethical statement:** This study was approved Ethical approval was obtained from Romagna
33
34 333 Ethics Committee (CEROM), study ID 2108, prot. n. IRST 100.28 of 10/04/2020, will be
35
36 334 conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice
37
38 335 guidelines. Informed consent will be obtained from all individual study participants before
39
40 336 enrollment.

41
42 337 **Competing interests:** None declared.

43
44
45 338 **Funding:** This research received no specific grant from any funding agency in the public,
46
47 339 commercial or not-for-profit sectors.
48
49
50
51
52
53
54
55
56
57
58
59
60

341 **REFERENCES**

- 342 1 Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med* 2005;353:487-97.
- 343 2 Brown MT, Bussell JK. Medication adherence: WHO cares? *Mayo Clin Proc*
344 2011;86:304-14.
- 345 3 Huang WC, Chen CY, Lin SJ, *et al.* Medication adherence to oral anticancer drugs:
346 systematic review. *Expert Rev Anticancer Ther* 2016;16:423-32.
- 347 4 Bergsbaken JJ, Eickhoff JC, Buss BA, *et al.* Assessment of adherence with oral
348 anticancer agents in oncology clinical trials: A systematic review. *J Oncol Pharm Pract*
349 2016;22:105-13.
- 350 5 Greer JA, Amoyal N, Nisotel L, *et al.* A Systematic Review of Adherence to Oral
351 Antineoplastic Therapies. *Oncologist* 2016;21:354-76.
- 352 6 Fenerty SD, West C, Davis SA, *et al.* The effect of reminder systems on patients'
353 adherence to treatment. *Patient Prefer Adherence* 2012;6:127-35.
- 354 7 Vervloet M, van Dijk L, Santen-Reestman J, *et al.* SMS reminders improve adherence
355 to oral medication in type 2 diabetes patients who are real time electronically
356 monitored. *Int J Med Inform* 2012;81:594-604.
- 357 8 Oakley C, Lennan E, Roe H, *et al.* Safe practice and nursing care of patients receiving
358 oral anti-cancer medicines: a position statement from UKONS. *Ecancermedicalscience*
359 2010;4:177.
- 360 9 Mathes T, Antoine SL, Pieper D, *et al.* Adherence enhancing interventions for oral
361 anticancer agents: a systematic review. *Cancer Treat Rev* 2014;40:102-8.
- 362 10 Gebbia V, Bellavia M, Banna GL, *et al.* Treatment monitoring program for
363 implementation of adherence to second-line erlotinib for advanced non-small-cell lung

- 1
2
3
4 364 cancer. *Clin Lung Cancer* 2013;14:390-8.
5
6 365 11 Simons S, Ringsdorf S, Braun M, *et al.* Enhancing adherence to capecitabine
7
8 366 chemotherapy by means of multidisciplinary pharmaceutical care. *Support Care Cancer*
9
10 367 2011;19:1009-18.
11
12 368 12 Weaver A, Young AM, Rowntree J, *et al.* Application of mobile phone technology for
13
14 369 managing chemotherapy-associated side-effects. *Ann Oncol* 2007;18:1887-92.
15
16 370 13 Paré G, Moqadem K, Pineau G, *et al.* Clinical effects of home telemonitoring in the
17
18 371 context of diabetes, asthma, heart failure and hypertension: a systematic review. *J Med*
19
20 372 *Internet Res* 2010;12:e21.
21
22 373 14 Polisen J, Tran K, Cimon K, *et al.* Home telehealth for chronic obstructive pulmonary
23
24 374 disease: a systematic review and meta-analysis. *J Telemed Telecare* 2010;16:120-7.
25
26 375 15 Polisen J, Tran K, Cimon K, *et al.* Home telemonitoring for congestive heart failure: a
27
28 376 systematic review and meta-analysis. *J Telemed Telecare* 2010;16:68-76.
29
30 377 16 Galligioni E, Piras EM, Galvagni M, *et al.* Integrating mHealth in Oncology:
31
32 378 Experience in the Province of Trento. *J Med Internet Res* 2015;17:e114.
33
34 379 17 Galligioni E, Berloff F, Caffo O, *et al.* Development and daily use of an electronic
35
36 380 oncological patient record for the total management of cancer patients: 7 years'
37
38 381 experience. *Ann Oncol* 2009;20:349-52.
39
40 382 18 Eccher C, Gios L, Zanutto A, *et al.* TreC platform. An integrated and evolving care
41
42 383 model for patients' empowerment and data repository. *J Biomed Inform*
43
44 384 2020;102:103359.
45
46 385 19 Eccher C, Piras EM, Stenico M. TreC - a REST-based regional PHR. *Stud Health*
47
48 386 *Technol Inform* 2011;169:108-12.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 387 20 Passardi A, Rizzo M, Maines F, *et al.* Optimisation and validation of a remote
5
6 388 monitoring system (Onco-TreC) for home-based management of oral anticancer
7
8 389 therapies: an Italian multicentre feasibility study. *BMJ Open* 2017;7:e014617.
9
10
11 390 21 Brooke, J. SUS: A “quick and dirty” usability scale. In: Jordan PW, Thomas B,
12
13 391 Weerdmeester BA, editors. Usability Evaluation in Industry. London: Taylor & Francis;
14
15 392 1996:189-94.
16
17
18 393 22 Medeiros KS, Queiroz JF, Monteiro MN, *et al.* Impact of mobile applications on
19
20 394 adherence to cancer treatment: a systematic review and metaanalysis protocol *BMJ*
21
22 395 *Open* 2019;9:e027246.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

er review only



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	ItemNo	Description	
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	The Title is structured accordingly (page 1)
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	ClinicalTrials.gov NCT04826458 (Page 4)
Protocol version	3	Date and version identifier	Page 4
Funding	4	Sources and types of financial, material, and other support	Page 17
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	Page 1
	5b	Name and contact information for the trial sponsor	NA, this is a non-industry-sponsored trial

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 5c Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities **NA, this is a non-industry-sponsored trial**
- 5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee) **IRST is the coordinating centre of this study; the chief and co-chief investigators are Dr. Patrizia Serra (senior clinical research coordinator) and Dr. Alessandro Passardi (clinician). The coordinating centre has a core facility for the design and conduction of clinical trials, that is, the Biostatistics and Clinical Trials Unit. This unit is composed by study coordinators, monitors, and biostatisticians who support the principal investigators from the design of the study until its closure.**

Introduction

Background and rationale

- 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention

Pages 6,7

- 6b Explanation for choice of comparators

Pages 6,7

Objectives

- 7 Specific objectives or hypotheses

Page 7

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	Page 7 (in Methods and Analysis), lines 138-40
--------------	---	---	--

16
17
18

Methods: Participants, interventions, and outcomes

19
20
21
22
23
24
25
26
27
28
29
30

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	Page 9 (in Methods and Analysis) lines 153-155
---------------	---	--	--

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Page 8, lines 143-150
----------------------	----	--	-----------------------

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	Page 10
---------------	-----	--	---------

1			
2		11b	Criteria for
3			discontinuing or
4			modifying allocated
5			interventions for a
6			given trial participant
7			(eg, drug dose
8			change in response to
9			harms, participant
10			request, or
11			improving/worsening
12			disease)
13			
14			
15			
16		11c	Strategies to improve
17			adherence to
18			intervention protocols,
19			and any procedures
20			for monitoring
21			adherence (eg, drug
22			tablet return,
23			laboratory tests)
24			
25			
26			
27		11d	Relevant concomitant
28			care and interventions
29			that are permitted or
30			prohibited during the
31			trial
32			
33			
34	Outcomes	12	Primary, secondary,
35			and other outcomes,
36			including the specific
37			measurement variable
38			(eg, systolic blood
39			pressure), analysis
40			metric (eg, change
41			from baseline, final
42			value, time to event),
43			method of
44			aggregation (eg,
45			median, proportion),
46			and time point for
47			each outcome.
48			Explanation of the
49			clinical relevance of
50			chosen efficacy and
51			harm outcomes is
52			strongly
53			recommended
54			
55			
56			
57			
58			
59			
60			

Page 10, the observation period will end earlier than planned for disease progression, unacceptable toxicity or patient refusal (lines 222-225)

Pages 10,11. Patients will be closely monitored and trained by the clinician or the counsellor at the beginning of the study as well as, if necessary, at the following clinical visits.

Page 8

Pages 11-13

1				
2	Participant	13	Time schedule of	Pages 10-11. Other than a description of
3	timeline		enrolment,	
4			interventions	
5			(including any run-ins	
6			and washouts),	
7			assessments, and	
8			visits for participants.	
9			A schematic diagram	
10			is highly	
11			recommended (see	
12			Figure)	
13				
14				
15				
16	Sample size	14	Estimated number of	
17			participants needed to	
18			achieve study	
19			objectives and how it	
20			was determined,	
21			including clinical and	
22			statistical	
23			assumptions	
24			supporting any	
25			sample size	
26			calculations	
27				
28				
29				
30	Recruitment	15	Strategies for	The eligibility criteria are wide favouring
31			achieving adequate	
32			participant enrolment	
33			to reach target	
34			sample size	
35				
36				
37				
38				
39				

Methods: Assignment of interventions (for controlled trials)

Allocation:

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Page 9
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	Page 9
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	Page 9

1				
2	Blinding	17a	Who will be blinded	Page 8, this is an open label trial
3	(masking)		after assignment to	
4			interventions (eg, trial	
5			participants, care	
6			providers, outcome	
7			assessors, data	
8			analysts), and how	
9				
10				
11		17b	If blinded,	NA
12			circumstances under	
13			which unblinding is	
14			permissible, and	
15			procedure for	
16			revealing a	
17			participant's allocated	
18			intervention during	
19			the trial	
20				
21				
22				

Methods: Data collection, management, and analysis

23				
24				
25				
26	Data collection	18a	Plans for assessment	Study procedures (Page 11) and
27	methods		and collection of	data management (Pages 13-14).
28			outcome, baseline,	
29			and other trial data,	
30			including any related	
31			processes to promote	
32			data quality (eg,	
33			duplicate	
34			measurements,	
35			training of assessors)	
36			and a description of	
37			study instruments (eg,	
38			questionnaires,	
39			laboratory tests) along	
40			with their reliability	
41			and validity, if known.	
42			Reference to where	
43			data collection forms	
44			can be found, if not in	
45			the protocol	
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1			
2		18b	Plans to promote
3			participant retention
4			and complete follow-
5			up, including list of
6			any outcome data to
7			be collected for
8			participants who
9			discontinue or deviate
10			from intervention
11			protocols
12			
13			
14			
15	Data	19	Plans for data entry,
16	management		coding, security, and
17			storage, including any
18			related processes to
19			promote data quality
20			(eg, double data
21			entry; range checks
22			for data values).
23			Reference to where
24			details of data
25			management
26			procedures can be
27			found, if not in the
28			protocol
29			
30			
31			
32			
33	Statistical	20a	Statistical methods for
34	methods		analysing primary and
35			secondary outcomes.
36			Reference to where
37			other details of the
38			statistical analysis
39			plan can be found, if
40			not in the protocol
41			
42			
43			
44		20b	Methods for any
45			additional analyses
46			(eg, subgroup and
47			adjusted analyses)
48			
49			
50		20c	Definition of analysis
51			population relating to
52			protocol non-
53			adherence (eg, as
54			randomised analysis),
55			and any statistical
56			methods to handle
57			missing data (eg,
58			multiple imputation)
59			
60			

This aspect was taken into account during the trial design, especially with respect to the definition of duration of follow-up. That is, defining an intervention window not too short and not too long. Reasons for early termination are collected in the eCRFs.

Page 13 (Data management)

Page 14

NA

Page 14

1
2 **Methods: Monitoring**

3
4 Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25 21b Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial
26
27
28
29
30
31
32
33
34
35
36 Harms 22 Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct
37
38
39
40
41
42
43
44
45
46
47
48
49 Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor
50
51
52
53
54
55
56
57
58
59
60

Given the nature of the study, eg. not testing a new drug, not having serious safety concerns or unknown risks (the intervention under study here is an electronic diary), not having any regulatory approval intent, the DMC was not included.

NA, no interim analyses were planned

NA

NA

Ethics and dissemination

1			
2			
3			
4	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval
5			Page 15
6			
7			
8			
9			
10			
11	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)
12			Page 15. Ethical committee approval is required before any protocol amendment is implemented.
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)
29			Page 9 (recruitment)
30			
31			
32			
33			
34			
35			
36			
37			
38		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable
39			NA, no ancillary studies are planned
40			
41			
42			
43			
44			
45			
46			
47	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial
48			Page 15
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

1				
2	Declaration of	28	Financial and other	Page 17
3	interests		competing interests	
4			for principal	
5			investigators for the	
6			overall trial and each	
7			study site	
8				
9				
10	Access to data	29	Statement of who will	Page 15
11			have access to the	
12			final trial dataset, and	
13			disclosure of	
14			contractual	
15			agreements that limit	
16			such access for	
17			investigators	
18				
19				
20				
21	Ancillary and	30	Provisions, if any, for	NA
22	post-trial care		ancillary and post-trial	
23			care, and for	
24			compensation to	
25			those who suffer harm	
26			from trial participation	
27				
28				
29	Dissemination	31a	Plans for investigators	Page 15
30	policy		and sponsor to	
31			communicate trial	
32			results to participants,	
33			healthcare	
34			professionals, the	
35			public, and other	
36			relevant groups (eg,	
37			via publication,	
38			reporting in results	
39			databases, or other	
40			data sharing	
41			arrangements),	
42			including any	
43			publication restrictions	
44				
45				
46				
47				
48		31b	Authorship eligibility	Authorship will be proportional to the
49			guidelines and any	accrual of each center. No professional
50			intended use of	writer will be used.
51			professional writers	
52				
53				
54				
55				
56				
57				
58				
59				
60				

1
2 31c Plans, if any, for [See IPD statement on clinicaltrials.gov](https://clinicaltrials.gov)
3 granting public access
4 to the full protocol,
5 participant-level
6 dataset, and statistical
7 code
8
9

10 Appendices

11
12 Informed consent 32 Model consent form [This information can be found](#)
13 materials and other related [in the study protocol but not in the](#)
14 documentation given [manuscript.](#)
15 to participants and
16 authorised surrogates
17
18
19 Biological 33 Plans for collection, [NA](#)
20 specimens laboratory evaluation,
21 and storage of
22 biological specimens
23 for genetic or
24 molecular analysis in
25 the current trial and
26 for future use in
27 ancillary studies, if
28 applicable
29
30
31

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60